Inhibition of the Activities of Reverse Transcriptase and Integrase of Human Immunodeficiency Virus Type-1 by Peptides Derived from the Homologous Viral Protein R (Vpr)

Journal of Molecular Biology

Volumn 369, Issue 5, 2007, Pages 1230-1243

  Gleenberg, Iris Oz ^a   Herschhorn, Alon ^a   Hizi, Amnon ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

HIV 1; integrase, viral protein R; peptides; reverse transcriptase

Indexed keywords

AMINO ACID; INTEGRASE; INTEGRASE INHIBITOR; PEPTIDE; PEPTIDE LIBRARY; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS PROTEIN; VPR PROTEIN;

AMINO TERMINAL SEQUENCE; ANTIVIRAL ACTIVITY; ARTICLE; BINDING KINETICS; CARBOXY TERMINAL SEQUENCE; CONFORMATIONAL TRANSITION; DIMERIZATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; MOLECULAR INTERACTION; MOLECULAR MODEL; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN DOMAIN; STEREOSPECIFICITY;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 34248633747     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2007.03.073     Document Type: Article

References (52)

1. Nermut M.V., and Fassati A. Structural analyses of purified human immunodeficiency virus type 1 intracellular reverse transcription complexes. J. Virol. 77 (2003) 8196-8206
2. Miller M.D., Farnet C.M., and Bushman F.D. Human immunodeficiency virus type 1 preintegration complexes: studies of organization and composition. J. Virol. 71 (1997) 5382-5390
3. Iordanskiy S., Berro R., Altieri1 M., Kashanchi F., and Bukrinsky M. Intracytoplasmic maturation of the human immunodeficiency virus type 1 reverse transcription complexes determines their capacity to integrate into chromatin. Retrovirology 3 (2006) 4 10.1186/1742-4690-3-4
4. Bukrinsky M. A hard way to the nucleus. Mol. Med. 10 (2004) 1-6
5. Fouchier R.A.M., and Malim M.H. Nuclear import of human immunodeficiency virus type-1 preintegration complexes. Adv. Virus Res. 52 (1999) 275-299
6. Coffin J.M., Hughes S.H., and Varmus H.E. Retroviruses (1997), Cold Spring Harbor Laboratories Press, Cold Spring Harbor, NY
7. Thang K.C., and Davies D.R. Structure and function of HIV-1 integrase. Curr. Top. Med. Chem. 4 (2004) 965-979
8. Le Rouzic E., and Benichou S. The Vpr protein from HIV-1: distinct roles along the viral life cycle. Retrovirology 2 (2005) 11 10.1186/1742-4690-2-11
9. Parithosh K.T., Bassel E.S., Velpandi A., Ramachandran M., and Alagarsamy S. HIV-1 Vpr: genetic diversity and functional features from the perspective of structure. DNA Cell Biol. 23 (2004) 207-222
10. Oz Gleenberg I., Avidan O., Goldgur Y., Herschhorn A., and Hizi A. Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase. J. Biol. Chem. 280 (2005) 21987-21996
11. Tasara T., Maga G., Hottiger O.M., and Hübscher U. HIV-1 reverse transcriptase and integrase enzymes physically interact and inhibit each other. FEBS Letters 507 (2001) 39-44
12. Oz Gleenberg I., Herschhorn A., Goldgur Y., and Hizi A. Inhibition of human immunodeficiency virus type-1 reverse transcriptase by a novel peptide derived from the viral integrase. Arch. Biochem. Biophys. 458 (2007) 202-212
13. Gallay P., Swingler S., Song J., Bushman F.D., and Trono D. HIV nuclear import is governed by the phosphotyrosine-mediated binding of matrix to the core domain of integrase. Cell 83 (1995) 569-576
14. Bischerour J., Tauc P., Leh H., de Rocquigny H., Roques B.P., and Mouscadet J.-F. The (52-96) C-terminal domain of Vpr stimulates HIV-1 IN-mediated homologous strand transfer of mini-viral DNA. Nucl. Acids Res. 31 (2003) 2694-2702
15. Oz I., Avidan O., and Hizi A. Inhibition of the integrases of human immunodeficiency viruses type 1 and type 2 by reverse transcriptases. Biochem. J. 361 (2002) 557-566
16. Hehl A.E., Joshi P., Kalpana V.G., and Prasad R.V. Interaction between human immunodeficiency virus type-1 reverse transcriptase and integrase proteins. J. Virol. 78 (2004) 5056-5067
17. Avidan O., Entin Meer M., Oz I., and Hizi A. The processivity and fidelity of DNA synthesis exhibited by the reverse transcriptase of bovine leukemia virus. Eur. J. Biochem. 269 (2002) 859-867
18. Engelman A., and Craigie R. Identification of conserved amino acid residues critical for human immunodeficiency virus type 1 integrase function in vitro. J. Virol. 66 (1992) 6361-6369
19. Kino T., and Pavlakis G.N. Partner molecules of accessory protein Vpr of the human immunodeficiency virus type 1. DNA Cell Biol. 23 (2004) 193-205
20. Schuler W., Wecker K., de Rocquigny H., Baudat Y., Sire J., and Roques B.P. NMR structure of the (52-96) C-terminal domain of the HIV-1 regulatory protein Vpr: molecular insights into its biological functions. J. Mol. Biol. 285 (1999) 2105-2117
21. Bourbigot S., Beltz H., Denis J., Morellet N., Roques B., Mily Y., and Bouaziz S. The C-terminal domain of the HIV-1 regulatory protein Vpr adopts an antiparallel dimeric structure in solution via its leucine-zipper-like domain. Biochem. J. 387 (2005) 333-341
22. Yao X.J., Subbramanian R.A., Rougeau N., Boisvert F., Bergeron D., and Cohen E.A. Mutagenic analysis of human immunodeficiency virus type 1 Vpr: role of a predicted N-terminal alpha-helical structure in Vpr nuclear localization and virion incorporation. J. Virol. 69 (1995) 7032-7044
23. Engler A., Stangler T., and Willbold D. Structure of human immunodeficiency virus type 1 Vpr (34-51) peptide in micelle containing aqueous solution. Eur. J. Biochem. 269 (2002) 3264-3269
24. Wecker K., and Roques B.P. NMR structure of the (1-51) N-terminal domain of the HIV-1 regulatory protein Vpr. Eur. J. Biochem. 266 (1999) 359-369
25. Morellet N., Bouaziz S., Lenoir C., and Roques B.P. NMR structure of the HIV-1 regulatory protein Vpr. J. Mol. Biol. 327 (2003) 215-227
26. de Rocquigny H., Caneparo A., Delaunay T., Bischerour J., Mouscadet J.F., and Roques B.P. Interactions of the C-terminus of viral protein R with nucleic acids are modulated by its N- terminus. Eur. J. Biochem. 267 (2000) 3654-3660
27. Zhang S., Pointer D., Singer G., Feng Y., Park K., and Zhao L.J. Direct binding to nucleic acids by Vpr of human immunodeficiency virus type 1. Gene 212 (1998) 157-166
28. Jacobo-Molina A., Ding J., Nanni R.G., Clark Jr. A.D., Lu X., Tantillo C., et al. Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 Å resolution shows bent DNA. Proc. Natl Acad. Sci. USA 90 (1993) 6320-6324
29. Bebenek K., Beard W.A., Darden T.A., Li L., Prasad R., Luxon B.A., et al. A minor groove binding track in reverse transcriptase. Nature Struct. Biol. 4 (1997) 194-197
30. Latham G.J., Forgacs E., Beard W.A., Prasad R., Bebenek K., Kunkel T.A., et al. Vertical-scanning mutagenesis of a critical tryptophan in the "minor groove binding track" of HIV-1 reverse transcriptase. Major groove DNA adducts identify specific protein interactions in the minor groove. J. Biol. Chem. 275 (2000) 15025-15033
31. Jacobo-Molina A., and Arnold E. HIV reverse transcriptase structure-function relationship. Biochemistry 30 (1991) 6351-6356
32. Sevilya Z., Loya S., Hughes S.H., and Hizi A. The ribonuclease H activity of the reverse transcriptases of human immunodeficiency viruses type 1 and type 2 is affected by the thumb subdomain of the small protein subunits. J. Mol. Biol. 341 (2001) 957-971
33. Sevilya Z., Loya S., Adir N., and Hizi A. The ribonuclease H activity of the reverse transcriptase of human immunodeficiency virus type-1 and type-2 is modulated by residue 294 of the small subunits. Nucl. Acids Res. 31 (2003) 1481-1487
34. Sevilya Z., Loya S., Duvshani A., Adir N., and Hizi A. Mutagenesis of cysteine 280 of the reverse transcriptase of human immunodeficiency virus type-1: the effects on the ribonuclease H activity. J. Mol. Biol. 327 (2003) 19-30
35. Sluis-Cremer N., and Tachedjian G. Modulation of the oligomeric structures of HIV-1 retroviral enzymes by synthetic peptides and small molecules. Eur. J. Biochem. 269 (2002) 5103-5111
36. Dyda F., Hickman A.B., Jenkins T.M., Engelman A., Craigie R., and Davies D.R. Crystal structure of the catalytic domain of HIV-1 integrase: similarity to other polynucleotidyl transferases. Science 266 (1994) 1981-1986
37. Yang W., and Steitz T.A. Recombining the structures of HIV integrase, RuvC and RNase H. Structure 3 (1995) 131-134
38. de Soultrait V.R., Lozach P.-Y., Altmeyer R., Tarrago-Litvak L., Litvak S., and Andreola M.L. DNA aptamers derived from HIV-1 RNase H inhibitors are strong anti-integrase agents. J. Mol. Biol. 324 (2002) 195-203
39. Fassati A., and Goff S.P. Characterization of intracellular reverse transcription complexes of human immunodeficiency virus type 1. J. Virol. 75 (2001) 3626-3635
40. Khiytani D.K., and Dimmock N.J. Characterization of a human immunodeficiency virus type 1 pre-integration complex in which the majority of the cDNA is resistant to DNase I digestion. J. Gen. Virol. 83 (2002) 2523-2532
41. Druillennec S., Dong C.Z., Escaich S., Gresh N., Bousseau A., Roques B.P., and Fournie-Zaluski M.C. A mimic of HIV-1 nucleocapsid protein impairs reverse transcription and displays antiviral activity. Proc. Natl Acad. Sci. USA 96 (1999) 4886-4891
42. Morris M.C., Robert-Hebmann V., Chaloin L., Mery J., Heit F., Devaux C., et al. A new potent HIV-1 reverse transcriptase inhibitor. A synthetic peptide derived from the interface subunit domains. J. Biol. Chem. 274 (1999) 24941-24946
43. de Soultrait V.R., Caumont A., Parissi V., Morellet N., Ventura M., Lenoir C., et al. A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase. J. Mol. Biol. 318 (2002) 45-58
44. Yung E., Sorini M., Pal A., Craig E., Morozov A., Delattre O., et al. Inhibition of HIV-1 virion production by a transdominant mutant of integrase interactor 1. Nature Med. 7 (2001) 920-926
45. Barsov E.V., Huber W.E., Marcotrigiano J., Clark P.K., Clark A.D., Arnold E., and Hughes S.H. Inhibition of human immunodeficiency virus type 1 integrase by the Fab fragment of a specific monoclonal antibody suggests that different multimerization states are required for different enzymatic functions. J. Virol. 70 (1996) 4484-4494
46. Boyer P.L., Ding J., Arnold E., and Hughes S.H. Subunit specificity of mutations that confer resistance to nonnucleoside inhibitors in human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 38 (1994) 1909-1914
47. Hizi A., Tal R., Shaharabany M., and Loya S. Catalytic properties of the reverse transcriptases of human immunodeficiency viruses type 1 and type 2. J. Biol. Chem. 266 (1991) 6230-6239
48. Tovchigrechko A., and Vakser I.A. GRAMM-X public web server for protein-protein docking. Nucl. Acids Res. 34 (2006) W310-W314
49. Ren J., Esnouf R., Garman E., Somers D., Ross C., Kirby I., et al. High resolution structures of HIV-1 RT from four RT-inhibitor complexes. Nature Struct. Biol. 2 (1995) 293-302
50. Goldgur Y., Dyda F., Hickman A.B., Jenkins T.M., Craigie R., and Davies D.R. Three new structures of the core domain of HIV-1 integrase: an active site that binds magnesium. Proc. Natl Acad. Sci. USA 95 (1998) 9150-9154
51. Yao S.G., Azad A.A., Macreadie I.G., and Norton R.S. Helical structure of polypeptides from the C-terminal half of HIV-1 Vpr. Protein Peptides Letters 5 (1998) 127-134
52. Yao S., Torres A.M., Azad A.A., Macreadie I.G., and Norton R.S. Solution structure of peptides from HIV-1 Vpr protein that cause membrane permeabilization and growth arrest. J. Peptide Sci. 4 (1998) 426-435